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Abstract 
Background: To assess clinical application of computed tomography (CT)-guided 125I seed implantation for patients 
who cannot endure or unwillingly receive repeated surgery, chemotherapy, or radiotherapy for unmanageable cervi-
cal lymph node metastases in head and neck cancer (HNC).
Methods: Thirty-one consecutive patients received CT-guided 125I seed implantation between February 2010 and 
December 2013. To evaluate the clinical efficiency, karnofsky performance score (KPS), numeric rating scale (NRS), and 
tumor volume at 3-, and 6-month post-implantation were compared with pre-implantation, along with local control 
rate (LCR), overall survival rate (OSR), and complications at 3, 6 months, 1, and 2 years.
Results: The tumor volume was obviously decreased at 3-, and 6-month post-implantation (21.23 ± 8.83 versus 
9.19 ± 7.52 cm2; 21.23 ± 8.83 versus 6.42 ± 9.79 cm2; P < 0.05) compared with pre-implantation. The NRS was statisti-
cally reduced (3.06 ± 1.06 versus 7.77 ± 0.92; 2.39 ± 1.15 versus 7.77 ± 0.92; P < 0.05), while KPS was significantly 
improved (83.18 ± 5.97 versus 73.60 ± 7.90; 82.86 ± 5.43 versus 73.60 ± 7.90; P < 0.05) postoperatively at 3 and 
6 months, respectively. The LCR at 3, 6 months, 1, and 2 years was 96.30, 83.87, 64.51, and 45.16 %, respectively. The 
OSR was 100, 100, 67.74, and 45.16 %, respectively. Three cases experienced grade I and two had grade II acute radia-
tion toxicity.
Conclusions: CT-guided seed implantation may be feasible and safe for HNC patients whose neck nodes are not 
manageable by routine strategies with fewer complications, higher LCR, and significant pain relief.
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Background
Head and neck cancer (HNC) is a broad term encom-
passing epithelial malignancies, which is the sixth most 
common type of cancer in the world [1]. The incidence 
of this disease is increasing worldwide [2, 3]. Although 
advances in multimodality therapies (for example, sur-
gery combined with adjuvant external-beam radiotherapy 
(EBRT), or adjuvant radiochemotherapy) for patients 
with HNC, the clinical outcomes are still poor [4]. The 
5-year survival rate remains relatively unchanged for 
the past 30 years [5, 6]. Cervical lymph node metastasis 
might contribute to this bleak scenario [7], because HNC 
has a high propensity to metastasize to locoregional 
lymph nodes due to the rich lymphatic system [8]. More-
over, the presence of cervical lymph node metastasis is 
now considered as the single most adverse independent 
prognostic factor [8–12], and the status of lymph node 
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nearly 50 % [13, 14]. Therefore, it is necessary to search 
an effective therapeutic regimen.
In recent years, computed tomography (CT)-guided 
125I seed implantation has received much attention in the 
field of medical science. It is a minimally invasive brachy-
therapy technique that ensures protracted cell killing 
over a period of several months through targeted delivery 
of high-dose radiation. Accumulating evidence suggests 
that this technique is considered as an important sup-
plementary treatment for unresectable advanced HNC 
due to its ability to offer high precision, little invasive-
ness, strong lethality, and less complications [4, 15–18]. 
Moreover, these studies have shown that this technique 
offered significant improvement in clinical symptoms 
and life quality.
However, rare clinical data on the treatment of patients 
with cervical lymph node metastases in HNC have rarely 
been reported. In the present study, CT-guided 125I seed 
implantation was performed to patients with cervical 
lymph node metastases in HNC. The results identified 
by this study might contribute to a better evidence of 




This study was approved by The People’s Hospital of 
Liaoning Province Ethics Committee, and informed con-
sent was obtained from all the enrolled patients. Between 
February 2010 and December 2013, 31 consecutive 
patients with unmanageable cervical lymph node metas-
tases in HNC, including 19 men and 12 women, aged 
48–75  years (mean 67  years), who received CT-guided 
125I seed interstitial implantation in our hospital were 
included in this study. The source of the metastatic tumor 
included nine cases of nasopharyngeal carcinoma, eight 
cases of tongue cancer, five cases of laryngeal carcinoma, 
three cases of maxillary sinus carcinoma, and six cases of 
thyroid carcinoma. The previous surgeries performed on 
the patients included 18 cases of radical neck dissection 
(RND) and 13 cases of selective or modified neck dissec-
tion (MND). The primary tumor stage was all stage IV for 
all patients. The tumor-node-metastasis (TNM) staging 
included three cases of T3N3M1, 11 cases of T2N3M1, 
four cases of T2N2M1, six cases of T2N1M1, two cases 
of T3N1M1, one case of T1N1M1, one case of T1N3M1, 
one case of T4N3M1, one case of T1N2M1, and one case 
of T3N2M1. Among the 31 patients, 25 patients under-
went one surgery, while six patients underwent surgery 
twice. All patients had undergone prior adjuvant exter-
nal-beam radiation therapy (EBRT). Of these patients, 25 
patients underwent EBRT once, and six patients under-
went EBRT twice. The cumulative radiotherapy dose was 
28-90 GY (mean 66 ± 13.34 GY). In addition, six patients 
received chemotherapy for four cycles and eight patients 
accepted chemotherapy for three cycles (Table 1).
The indication for CT-guided 125I seed implantation 
was as follows: (1) clinically diagnosed as cervical lymph 
node metastasis, with HNC being confirmed by pathol-
ogy; (2) Karnofsky performance score (KPS)  ≥  60; (3) 
normal function in liver, kidneys, and heart; (4) persis-
tent pain of cervical tumors and treatment of medication, 
physical therapy, or other conservative therapy made no 
significant improvement; (5) expected lifetime was more 
than 3 months; (6) the trachea, esophagus or other vital 
organs were compressed by cervical metastatic tumor, 
which had seriously affected the quality of the patient’s 
life; and (7) patients were not suitable for reoperation, 
chemotherapy, or radiotherapy, or the patients were not 
willing to receive any chemotherapy or radiotherapy.
Equipment and CT‑guided implantation
Before the operation, the history and physical condition, 
hematological and chemical profiles of all the patients 
were evaluated. Additionally, each patient underwent a 
detailed tumor volume study using contrast-enhanced 
CT scanning (GE Lightspeed 64, General Electric Com-
pany, Fairfield, CT, USA, thickness = 5 mm) of the neck 
1 week before seed implantation (Fig. 1a). The planning 
target volume (PTV) was extended beyond the clini-
cal target volume (CTV) by a 1-cm margin, which was 
outlined by the radiation oncologist on each transverse 
image. Treatment Planning System (TPS, Prowess 3D, 
SSGI, Chico, CA, USA) was performed to calculate the 
dose distribution, which was based on the American 
Association of Physicists in Medicine TG43 brachyther-
apy formalism [19]. The 125I seed sources were purchased 
from ZhiBo Carve Out Development Ltd. Beijing, China. 
It releases rays with a nominal activity of 0.4–0.8  mCi/
seed, a half-life of 60.2 days, and a size of 0.8 × 0.45 mm. 
The 18-G implantation needles and turntable implanta-
tion gun (ZhiBo Carve out Development Ltd. Beijing, 
China) were utilized for seed implantation. The depth 
and angle of implantation needles were guided under 
CT supervision, avoiding important vessels and nerves. 
Patients were allowed a clear liquid diet for 24 h before 
the implantation. This procedure was carried out in 
a standard CT room under local anesthesia by using 
0.5  % lidocaine. The distance between the two adjacent 
implantation needles was about 1 cm (Fig. 1b). Repeated 
CT was performed within 24 h after the implantation to 
confirm the distribution of seeds, and then the images 
were collected and put into the TPS (Fig. 1c). Re-implan-
tation was performed if necessary. After the implanta-
tion, all patients were kept under observation, and then 
returned toward only if there was no sign or symptom of 
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Table 1 General characteristics of 31 patients
Patient  
no.



















2 63 M NPC IVT1N1M1 L 7 2 3*3 Cisplatin + fluo-
rouracil (4)
3 65 F NPC IVT2N3M1 L 7 2 6*3 Cisplatin + fluo-
rouracil (4)




5 55 F NPC IVT3N3M1 R 9 2 7*4
6 61 M NPC IVT2N1M1 R 9 3 5*2 Cisplatin + fluo-
rouracil (3)
7 63 F NPC IVT2N1M1 L 8 3 5*4 Cisplatin + fluo-
rouracil (3)
8 54 F NPC IVT1N3M1 R 7 3 6*3 Radiotherapy (2)
9 52 M NPC IVT4N3M1 L 9 2 8*5 Cisplatin + fluo-
rouracil (4) 
surgery (2)
10 70 M Tongue cancer IVT1N2M1 R 8 2 3*3
11 65 M Tongue cancer IVT2N3M1 L 7 3 5*3 Cisplatin vincris-
tine metho-
trexate (3)
12 72 F Tongue cancer IVT2N2M1 L 8 2 5*4
13 68 M Tongue cancer IVT2N3M1 R 6 2 4*4 Cisplatin vincris-
tine metho-
trexate (3)
14 74 M Tongue cancer IVT2N3M1 L 8 2 5*4 Radiotherapy (2)
15 71 F Tongue cancer IVT2N3M1 R 7 1 4*3
16 69 F Tongue cancer IVT2N3M1 R 7 2 4*4 Cisplatin vincris-
tine metho-
trexate (3)
17 67 F Tongue cancer IVT3N3M1 L 9 3 6*7 Cisplatin vincris-
tine metho-
trexate (3)
18 75 M Laryngocarci-
noma
IVT2N3M1 R 9 2 5*4 Surgery (2)
19 69 M Laryngocarci-
noma
IVT3N2M1 R 8 3 7*4
20 70 M Laryngocarci-
noma
IVT2N3M1 R 9 2 5*3 Radiotherapy (2)
21 73 M Laryngocarci-
noma
IVT2N3M1 R 8 2 6*5
22 70 F Laryngocarci-
noma
IVT2N2M1 R 9 2 4*4 Surgery (2)
23 75 M Maxillary sinus 
carcinoma
IVT2N3M1 R 8 2 6*4 Carboplatin (4)
24 70 M Maxillary sinus 
carcinoma
IVT2N2M1 R 7 2 5*4 Cisplatin (3)
25 51 F Maxillary sinus 
carcinoma
IVT2N3M1 L 6 2 6*4 Cisplatin (3)
26 75 F Thyroid cancer IVT2N1M1 R 7 8 6*5 Radiotherapy (2)
27 57 M Thyroid cancer IVT2N1M1 L 8 2 5*5
Page 4 of 8Huang et al. Eur J Med Res  (2016) 21:18 
complications, such as bleeding. Then, anti-inflamma-
tory and hemostasis were given to all the subjects after 
implantation.
Effect evaluation
Tumor response was evaluated according to the World 
Health Organization (WHO) standard criteria [20]. 
Tumor size was estimated from bidimensional measure-
ments (product of the longest diameter and its longest 
perpendicular diameter for each tumor). CT examination 
was conducted at 3 and 6 months after the implantation 
and classified as follows: a complete response (CR) indi-
cated the disappearance of all tumoral lesions lasting for 
more than 4 weeks; partial response (PR) indicated that 
total tumor size decreased at least a 50 %; stable disease 
(SD) indicated that total tumor size decreased by less 
than 50 % or increased by less than 25 %; and progressive 
disease (PD) indicated an exacerbation of tumor size at 
least a 25 % or lager.
In the present study, local control rate (LCR) was 
defined as the absence of tumor progression in CT 
(SD +  PR +  CR), while overall survival rate (OSR) was 
defined as the percentage of patients who are alive after 
a specified number of years of follow-up from the start 
point of post-implication to the end of follow-up or 
death.
The numerical rating scale (NRS) was used to meas-
ure of pain intensity before and after operation [21]. The 
NRS is an 11-point scale, which consists of integers from 
0 through 10 where 0 represents no pain; 1–3, mild pain 
without affecting sleep; 4–6, moderate pain; 7–9, severe 
pain (affect sleep or wake up from the pain); and 10 rep-
resents the worst imaginable pain. Patients were inquired 
for the pain degree and were required to select a single 
number during 0–11 that could best reveal their pain 
intensity and this selected number was the NRS.
Furthermore, a Radiation Therapy Oncology Group 
(RTOG) was utilized to assess the acute radiation mor-
bidity, and the RTOG/European Organization for 
Research and Treatment of Cancer (RTOG/EORTC) was 
employed to assess the latest radiation morbidity [22].
Follow‑up
All patients received follow-up phase immediately after 
the implantation. The follow-up period was 6–38 months, 
with first visits at the third month after intervention, and 
then subsequent follow-ups occurred at the 6 months, 1, 
and 2  years. The tumor volume was recorded at 3- and 



















28 61 M Thyroid cancer IVT3N1M1 R 9 2 5*3
29 59 F Thyroid cancer IVT2N1M1 L 7 2 4*4 Surgery (2)
30 48 M Thyroid cancer IVT3N1M1 L 7 2 5*4
31 74 M Thyroid cancer IVT2N1M1 L 8 2 6*5 Surgery (2)
Fig. 1 Treatment of a patient with cervical lymph node metastasis in primary nasopharyngeal carcinoma. a CT scan shows left neck lymph node 
metastasis before implantation. b CT scan shows that 125I seeds are implanted into the tumor via implantation needles. c CT scan shows that 125I 
seeds are implanted post-implantation 3 months. CT computed tomography
Page 5 of 8Huang et al. Eur J Med Res  (2016) 21:18 
6-month post-implantation using CT images. The LCR 
and OSR at 3, 6 months, 1 and 2 years were assessed. All 
patients successfully completed the follow-up.
Statistical analysis
All data were expressed as mean ± SD, and the statistical 
analysis was performed by using the SPSS software ver-
sion 19.0 (SPSS, Chicago, IL, USA). The median survival 
time of survival analysis was assessed by Kaplan–Meier 
methods. The difference of pain relief before and after 




The seed implantation procedure was successfully 
conducted in all patients. The implanted number of 
125I seeds was 16–84 (mean 46.13  ±  16.28) for each 
patient. The mean activity of each seed was 0.4–0.8 mCi 
(mean 0.65 ±  0.15). The D90 of 125I seeds ranged from 
90–125 Gy (mean 101.03 ± 8.54 Gy).
Response to treatment
After 125I seed interstitial implantation, the tumor vol-
ume was significantly reduced from 21.23  ±  8.83  cm2 
pre-implantation to 9.19 ± 7.52 and 6.42 ± 9.79 cm2 at 
3  months and 6  months after implantation (P  <  0.05) 
(Table  2; Fig.  2). Repeated CT conducted at 3-month 
post-implantation showed that there were three cases 
(9.68  %) in CR, 25 cases (80.65  %) in PR, two cases 
(6.45  %) in SD, and one case (3.22  %) in PD, respec-
tively. The NRS scores for pre-implantation, and 3- and 
6-month post-implantation were 7.77 ± 0.92, 3.06 ± 1.06, 
and 2.39  ±  1.15, respectively. Symptoms of pain were 
significantly reduced postoperatively at 3 and 6 months 
(P  <  0.05). Furthermore, KPS significantly improved 
at 3- and 6-month post-implantation compared with 
pre-implantation (83.18  ±  5.97 versus 73.60  ±  7.90; 
82.86 ± 5.43 versus 73.60 ± 7.90; P < 0.05), respectively. 
As shown in Fig. 3, the LCR at 3, 6 months, 1 and 2-years 
was 96.30, 83.87, 64.51, and 45.16  %, respectively. The 
OSR was 100, 100, 67.74, and 45.16 %, respectively. Four 
patients died of local recurrence; 11 patients died of lung 
metastasis; 13 patients died of recurrent tumor and dis-
tant metastases; and 3 patients had severe heart disease 
and died of heart disease, which was unrelated to the 
tumor.
Complications
Of all the patients, three patients suffered from fever 
post-implantation, but the fever did not exceeded 38.5 °C, 
and body temperature returned to normal in 3–5  days. 
Additionally, 3 and 2 patients developed grade I and 
grade II acute radiation toxicity on the skin (for example, 
faint or dull erythema/epilation/dry desquamation/mod-
erate edema) and mucous membrane (for example, mild/
moderate pain, patchy mucositis), respectively. Moreover, 
1, 2, and 1 patients experienced grade I, grade II, and late 
radiation toxicity on the skin (pigmentation change), sub-
cutaneous tissue (for example, slight in duration and loss 
of subcutaneous fat) and mucous membrane (dryness), 
respectively. Other tissues, such as the eyes, spinal cord, 
and lung, were not involved. No patients developed grade 
III, IV, or V acute/late radiation toxicity, or other serious 
complications (for example, massive hemorrhage, acute 
pulmonary embolism, or fistula).
Discussion
In the present study, 31 patients with unmanageable 
cervical lymph node metastases in HNC who could not 
undergo or not be willing to receive repeated surgery, 
chemotherapy, and radiotherapy (for example, EBRT) 
were enrolled. CT-guided 125I seed implantation was suc-
cessfully performed to all patients. The clinical applica-
tion of this technique was evaluated. The results showed 
that tumor volume and NRS scores were significantly 
reduced and KPS was significantly improved at 3- and 
6-month post-implantation compared with pre-implan-
tation. Additionally, fewer complications and higher LCR 
and OSR presented post-implantation.
For patients with either clinical positive or negative 
neck lymph node metastasis in HNC, high-dose radio-
therapy and radical surgery are the main treatments [12, 
23]. However, various postoperative pains and disorders 
might be induced [24], as well as radiation-associated 
normal tissue injury [25], even cerebrovascular disease 
[26, 27]. Although combined chemotherapy with radio-
therapy has been increasing, tumor control and survival 
remain disappointing [28]. Up to now, effective treat-
ments for this disease still remain challenging. Fortu-
nately, 125I radioactive seeds, which are considered as an 
effectively salvage or palliative treatment, have received 
Table 2 Effect evaluation of CT-guided 125I seed implanta-
tion
KPS Karnofsky performance score, NRS Numerical rating scale











21.23 ± 8.83 9.19 ± 7.52# 6.42 ± 9.79#
NRS 7.77 ± 0.92 3.06 ± 1.06# 2.39 ± 1.15#
KPS 73.60 ± 7.90 83.18 ± 5.97# 82.86 ± 5.43#
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increasing attention in the recent years. It has been suc-
cessfully applied to the treatment for various malignant 
tumors [29–31]. The major advantages of this technol-
ogy are its high dose of irradiation to the target area and 
low dose of irradiation to the surrounding normal tissue. 
Besides, this technology can maximize local control and 
minimize morbidity.
Recent studies have also been performed to present the 
clinical application of 125I seed implantation. Goffinet et al. 
[32] reported that the majority of patients with advanced 
recurrent HNC in his study had received prior to treat-
ment before 125I seed implantation. The results showed 
that a 70 % LCR was achieved. Park et al. [33] also reported 
that 35 patients with advanced recurrent squamous cell 
cancers of HNC received adjuvant 125I seed implants after 
surgical resection. The 5-year disease-free survival was 
41 %. A study conducted by Zhu et al. assessed the feasi-
bility, efficacy, and morbidity of 125I seed implantation for 
recurrent HNC after surgery and EBRT [16]. The results 
showed that the 1-, 2- and 3-year LCR were 73.3, 27.5, 
and 27.5  %, respectively, whereas the 1-, 2-, and 3  year 
OSR were 53.0, 18.2, and 18.2  %, respectively. Besides, a 
retrospective study on 14 patients with recurrent HNC 
underwent 125I seed implantation [4]. The results demon-
strated that the 1-, 2-, 3-, and 5-year LCR were 52, 39, 39, 
and 39 %, respectively, and the 1-, 2-, 3-, and 5-year OSR 
were 65, 39, 39, and 39  %, respectively. Similarly, in our 
study, the LCR at 3, 6 months, 1-, 2-year was 96.30, 83.87, 
64.51, and 45.16 %, respectively. The OSR were 100, 100, 
67.74, and 45.16 %, respectively. Our results were slightly 
different from the above previous studies. The main rea-
sons were listed as follows: (1) the number of patients and 
prior treatment before 125I seed implantation in our study 
were different from the above studies and (2) the patients 
in our study were all had cervical lymph node metas-
tasis. However, it is worth noting that the operation and 
chemoradiotherapy that the patients received prior to 125I 
seed implantation may not have an indirect impact on the 
results due to the similarity with the previous studies.
Moreover, in the present study, the NRS scores showed 
that the pain is significantly relieved in patients receiv-
ing 125I seeds implantation. This reduction in pain may 
be associated with the following factors: (1) tumor cells 
were killed, leading to the reduction of tumor volume, 
therefore the tension of tumor capsule declined and 
the compression of adjacent organs or peripheral nerve 
Fig. 2 Pre-implantation and post-implantation photos of the patient. a–c Masses in the neck of the patient before implantation. Neck masses were 
pointed by arrowheads. d Post-implantation photo shows that the neck masses are significantly reduced at 3 months after implantation
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relieved; (2) the expression of pain-related cytokines (e.g., 
5-hydroxytryptamine, bradykinin, and prostaglandin) 
was reduced; (3) the permeation of pain-related cytokines 
would be blocked by fibrosis or micro-vascular thrombo-
sis in the tumor or tissue adjacent to tumors; and (4) the 
conduction of pain would be blocked by the functional 
electrophysiological block or myelin degeneration of the 
nerve endings around tumor. Besides, KPS in our study 
was also significantly improved at 3- and 6-month post-
implantation. The above results suggested that 125I seed 
implantation may significantly relieve postoperative pain 
and improve the life quality of the patients. In addition, 
no patients showed serious complications shortly after 
implantation, while local skin pigmentation had a long-
term side effect. No obvious skin or mucosal ulcer was 
observed, and no serious adverse events such as hem-
orrhage and necrosis were reported. Excellent implant 
technology, which includes perfect protection for skin or 
mucosa inter-operatively, and a good distance between 
the seeds and the skin (approximately 1 cm), might effec-
tively avoid radioactive damage on the skin.
Conclusions
In conclusion, this study shows that CT-guided 125I seeds 
implantation is a minimally invasive technique in the treat-
ment of cervical metastatic tumors. It is characterized by 
higher precision and LCR, being microtraumatic and well-
tolerated, with fewer complications, and significant pain 
relief. It may provide an effective therapeutic measure in 
treatment of inoperable patients or the patients who are 
also not suitable for chemotherapy and radiotherapy with 
unmanageable cervical metastasis. Considering the short 
follow-up period involved in our study, a long-term fol-
low-up may be needed to acquire a definite conclusion.
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